Blog
RSS FeedPosted by Michael Wonder on 06 Mar 2017
Drug pricing report shows scope for more savings
6 March 2017 - The savings to the taxpayer in reducing the cost to Government of prescribed pharmaceuticals has been ...
Posted by Michael Wonder on 06 Mar 2017
Response to the Grattan Institute Report on medicine prices
6 March 2017 - Medicines Australia does not accept the findings of this latest inaccurate, selective and misleading Grattan Report ...
Posted by Michael Wonder on 06 Mar 2017
Chronic obstructive pulmonary disorder review - stakeholder forum
6 March 2017 - A stakeholder forum will be held for the post-market review of chronic obstructive pulmonary disorder medicines on ...
Posted by Michael Wonder on 05 Mar 2017
Australians paying four times above international prices for drugs
5 March 2017 - Yet another report from the Grattan Institute on the prices of off-patent medicines in the PBS; ...
Posted by Michael Wonder on 04 Mar 2017
Public Summary Documents - PBAC November 2016 meeting
3 March 2017 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the PBAC November 2016 ...
Posted by Michael Wonder on 04 Mar 2017
States urge hospitals to bill insurers
4 March 2017 - State governments are actively encouraging public hospitals to bill health insurers for their members’ treatment, driving ...
Posted by Michael Wonder on 04 Mar 2017
Agenda for the 8 March 2017 TC meeting
3 March 2017 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 03 Mar 2017
The scandal of generic drug pricing: drug regulation policies need review
23 February 2017 - We welcome the news that the Competitions and Market Authority is now taking drug companies such as ...
Posted by Michael Wonder on 03 Mar 2017
How to slash half a billion dollars a year from Australia’s drugs bill
3 March 2017 - Australia is spending more than A$500 million a year too much for pharmaceuticals because of a ...
Posted by Michael Wonder on 02 Mar 2017
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild type mCRC
2 March 2017 - NICE’s recommendation is a significant step forward in Merck’s aspiration to ensure cancer patients have optimal ...
Posted by Michael Wonder on 02 Mar 2017
NICE recommends Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis in England, Wales and Northern Ireland
2 March 2017 - Rapid NICE approval only two months after marketing authorisation in the EU; one of the fastest ...
Posted by Michael Wonder on 02 Mar 2017
Health funds’ hit list to save members $1.5bn a year
3 March 2017 - The private health insurance sector’s peak body has outlined measures in its pre-budget submission that it ...
Posted by Michael Wonder on 02 Mar 2017
NICE says patients accessing more cancer drugs following price drops
2 March 2017 - Patients will have routine access to more cancer drugs as companies have dropped their prices as part ...
Posted by Michael Wonder on 02 Mar 2017
Grant winners announced for new joint pharmaceuticals research fund
2 March 2017 - Researchers from Auckland and Otago Universities are the first recipients of new grants from PHARMAC and ...
Posted by Michael Wonder on 01 Mar 2017
'Give us the chance to live': mum suffering from breast cancer begs for life-extending drug Kadcyla to be available on NHS
1 March 2017 - Lesley Stephen watched her friend Annie die of cancer after being refused the drug and decided to ...